Login to Your Account



Scancell stops melanoma trial as DNA-based vaccine fails quality test

By Cormac Sheridan
Staff Writer

Friday, June 17, 2016

DUBLIN – Shares in Scancell Holdings plc fell over 16 percent Friday on news that the company had to bin supplies of its candidate DNA-based cancer vaccine SCIB1, as routine testing showed the clinical material no longer conformed to its original specification.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription